Document:

EX-10.2

 Exhibit 10.2 

March 16, 2015 
 Mr. Paul Estrem 

325 Clarewood Circle 
 Grayslake, IL 60030 

Dear Paul, 
 OFFER OF EMPLOYMENT

 As we have discussed, we are pleased to offer you continued employment at Melinta Therapeutics, Inc. (“Melinta”) as its Chief Financial
Officer (“CFO”), with the understanding that, at the discretion of Melinta, your title will change to that of Chief Operations Officer (“COO”). We are very enthusiastic about your continued employment with Melinta in this new
capacity, and are confident of a mutually beneficial relationship. 
 Position and Compensation 

As stated above, while at the present time, your position will remain CFO, it is expected that, at the request of Melinta, your duties will eventually
transition to those of Melinta’s COO. During this transition period, you will be expected to perform duties normally associated with both positions, with the expectation that once Melinta hires a new CFO (or at some other time as Melinta may
direct), your title would change to COO, and your duties will transition to those commensurate with someone in that position. For avoidance of doubt, until Melinta directs otherwise, you will be expected to (i) perform CFO duties (including,
but not limited to an S1 filing), (ii) perform COO duties (including the responsibilities generally described in the job description Melinta has shared with you), and (iii) help transition CFO responsibilities to the new CFO once he or she is
hired. For avoidance of doubt, Melinta will not ask you to perform two full jobs. Rather, as your CFO responsibilities decrease, your COO responsibilities will increase. 

You will continue to report directly to Mary Szela, Chief Executive Officer of Melinta. During the course of your employment with Melinta, your position and
duties are, of course, subject to change. As a Melinta employee, we expect that you will perform any and all duties and responsibilities normally associated with your position in a satisfactory manner and to the best of your abilities at all times.
In addition, you agree to observe and comply with all the rules, regulations, policies and procedures established by Melinta from time to time. Your performance will be reviewed formally at the end of the calendar year, and on a periodic basis
thereafter as long as you remain employed by Melinta. 
 Your base pay shall continue to be $13,164.84, payable semi-monthly (annualized to $315,956.25).
During each fiscal year of your employment with Melinta, you will be eligible for an annual bonus of up to 30% of your base salary contingent upon the successful achievement of corporate and individual performance goals. Any bonus to be paid will be
determined by the Compensation Committee of the Board of Directors of Melinta (the “Committee”) or its designee. Any annual bonus earned in respect of any year will be paid no later than 90 days following the end of such year. You must be
employed by Melinta on the date any bonus is paid in order to receive it. Melinta will review your compensation periodically. Your compensation also is subject to change, as Melinta considers necessary or appropriate. 

 Benefits 

Stock Options and Equity Grants: Your current Melinta stock options and/or equity grants awarded to you during your tenure as CFO shall continue to
accrue and vest in accordance with the terms of the grant documents and the terms of the applicable plans. Stock options and equity grants may be offered from time to time in the sole discretion of the Board of Directors and/or Committee depending
upon certain events, including for example the successful completion of corporate goals. 
 Retention Payments: In order to compensate you for your
continuing efforts as Melinta hires and transitions to its next CFO, Melinta will pay you a Retention Payment consistent with the conditions set forth in the letter attached hereto as Exhibit A, 

Severance: Melinta shall provide severance to you upon termination of your employment in accordance with the terms set forth in the Severance Agreement
dated November 8, 2013. You hereby agree that (i) agreeing to continued employment under the terms of this letter, (ii) accepting the transition to the COO role, (iii) transitioning CFO duties to a new CFO, and (iv) having
interim joint CFO/COO duties as described above, do not constitute a material adverse change to your primary responsibilities or duties (in connection with your employment under your original offer letter dated November 8, 2013), or any other
event that would constitute Good Reason for you to terminate your employment with Melinta (or which would otherwise provide you with any other reason for which you would become entitled to severance or other payments) pursuant to the terms of the
November 8, 2013 Severance Agreement. For avoidance of doubt, however, if Melinta terminates your employment during the period from the date of execution of this letter through December 31, 2015, the terms of the November 8, 2013
Severance Agreement shall apply. 
 Other Benefits: Melinta currently offers various benefits, including group medical and dental insurance, paid
time off (vacation and sick time), a 401(k) plan, short-term disability, long-term disability, and other benefits. These benefits may be modified or changed from time to time at the discretion of Melinta. The present benefit structure and other
important information about the benefits for which you may be eligible is described in other documents, which you either have already received, or will receive throughout the course of your employment. Where a particular benefit is subject to a
formal plan (i.e., medical insurance or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document. Should you have any questions regarding benefits, please see Human
Resources for a copy of the applicable plan document. 
 Expenses: Melinta will reimburse you for all reasonable and necessary expenses you incur in
connection with your employment with Melinta, subject to your presentment of appropriate documentation, in accordance with the published travel, meals and entertainment expense policies of Melinta. 

  
 2 

 Nature of Relationship 

As an at-will employee of Melinta, you will be expected to devote all of your working time to the performance of your
duties at Melinta throughout your employment with Melinta. Notwithstanding the foregoing, as long as it does not interfere, individually or in the aggregate, with the performance of your duties for Melinta or create a potential business or fiduciary
conflict, you may serve as an officer, director or trustee of, or otherwise participate in the activities of, educational, welfare, social, religious and civic organizations. While this letter reflects our commitment to employ you and we look
forward to a mutually rewarding relationship, this letter does not constitute a contract (express or implied) for a specific length of employment, and either party may choose to terminate the employment relationship upon written notice to the other
at any time and for any reason. Notwithstanding the at-will nature of your employment with Melinta, you agree to give the Chief Executive Officer at least four weeks’ advance written notice if you decide
to terminate your employment; provided, that Melinta may, in its sole and absolute discretion, by written notice accelerate such date of termination without changing the characterization of such termination. 

Taxes 
 Melinta may withhold from any payments made to you
all applicable taxes, including but not limited to income, employment, and social insurance taxes, as shall be required by law. 
 Noncompetition,
Nondisclosure and Developments Agreement 
 By accepting this offer of continued employment with Melinta, and as a condition of your continued employment
with Melinta, you hereby confirm your agreement to continue to comply with the terms and conditions of the Noncompetition, Nondisclosure and Developments Agreement you signed on November 11, 2013. Also, just as Melinta regards the protection of
its trade secrets, and other confidential information as a matter of great importance, we also respect that you may have an obligation to your prior employers to safeguard the confidential information of those companies, and we expect you to honor
them as well. To that end, we want to make it perfectly clear you should not bring with you to Melinta, or use in the performance of your responsibilities for Melinta any proprietary business or technical information, materials or documents of a
former employer. Finally, you hereby confirm that you have provided Melinta with a copy of any agreements with a former employer or other party that could restrict your professional activities in any way on behalf of Melinta. By signing this letter,
you represent and warrant to Melinta that you are under no contractual commitments inconsistent with your obligations to Melinta hereunder and that your acceptance of this offer of employment and your performance of the contemplated services
hereunder does not and will not conflict with or result in any breach or default under any agreement, contract or arrangement to which you are a party to or violate any other legal restriction. 

  
 3 

 Background Check; Authorization to Work 

Your initial offer of employment with Melinta was contingent on the acceptable results of a background check. As required by law, your employment with Melinta
is also contingent upon your providing legal proof of your identity and authorization to work in the United States within three (3) business days of your joining Melinta. You hereby confirm that no circumstances have changed that would
interfere with your ability to perform services on behalf of Melinta. 
 Entire Agreement 

This letter and Exhibit A, the November 8, 2013 Severance Agreement and the Employee Noncompetition, Nondisclosure and Developments Agreement you signed
on November 11, 2013 constitute our entire offer regarding the terms and conditions of your employment by Melinta. These supersede any prior agreements, or other promises or statements (whether oral or written) regarding the offered terms of
employment, including, but not limited to, the offer letter you signed on November 11, 2013. The terms of your employment shall be governed by and construed under the laws of the State of New York, without giving effect to conflict of laws
principles. 
 You may accept this offer of employment and the terms and conditions hereof by signing the enclosed additional copy of this letter. Your
signature on the copy of this letter and your submission of the signed copy to me will evidence your agreement with the terms and conditions set forth in this letter. Please return a copy of the offer letter to me. 

Sincerely, 
  

	
	 /s/ Mary Szela

	Mary Szela
	Chief Executive Officer
	
	Accepted and Agreed To:
	
	 /s/ Paul D. Estrem

	Paul Estrem
	
	3/16/15
	  
 Date

  
 4 

 RETENTION PACKAGE 

(EXHIBIT A TO OFFER OF EMPLOYMENT) 

Pursuant to the terms set forth in your Offer of Employment dated March 11, 2015, Melinta Therapeutics, Inc. (“Melinta” or the
“Company”) hereby extends to you the following retention package in connection with your continued employment with Melinta as its Chief Financial Officer (“CFO”), and eventually as its Chief Operations Officer (“COO”).
Melinta very much appreciates your continued cooperation and support. 
 Retention Payment 

In order to compensate you for your continuing efforts as the Company hires and transitions to its next CFO, Melinta will, consistent with the
conditions set forth in this letter agreement (the “Agreement”), pay you a Retention Payment (as defined below). 
 So long as you
have accepted continued employment with Melinta in accordance with the terms of the offer letter dated on or about March 11, 2015, and to the extent you remain employed through the applicable Retention Dates described below, Melinta will pay to
you either one retention payment or a series of retention payments (in sum, the “Retention Payment”), as soon as practicable following the applicable retention date, but in no event shall each retention payment be paid later than thirty
days following the applicable retention date. In order to be eligible to receive any portion of the Retention Payment, you must remain actively employed by Melinta on the applicable Retention Date, and continue to perform your work as required by
Melinta through that date. For avoidance of doubt, if, prior to the applicable Retention Date, (i) your employment is terminated by Melinta for Cause (as defined below), or (ii) you terminate your employment with Melinta for any reason,
you will not be eligible to receive the applicable Retention Payment(s) (or any portion thereof). 
 If on or prior to December 31,
2015, you have, in the sole discretion of Mary Szela, the Company’s CEO (the “CEO”), successfully performed your duties and responsibilities as directed by the CEO, including the achievement of the Milestones stated below, you shall
be eligible to receive a Retention Payment of up to $200,000, less applicable withholdings and deductions. Such Retention Payment shall be paid to you within sixty days following December 31,2015. 

Notwithstanding this, up to $100,000 of that Retention Payment may be paid to you prior to December 31, 2015, but only if you
successfully complete the milestones described below, in the discretion of the CEO. 
  

	1.	Milestone 1 (Audit): If the Audited Financial Statement and Associated Audit Opinion are issued by Deloitte on or prior to April 15, 2015, you shall be eligible to receive a retention payment of $25,000 (the
“Audit Retention Payment”) within thirty days following April 15, 2015 (the “Audit Retention Date”). 

	2.	Milestone 2 (Audit Controls Letter): If you complete the Audit Controls Letter with no Material Weaknesses other than those cited for insufficient staffing, and you complete and deliver such Audit Controls Letter
in a timely manner for Melinta to maintain a pre-July 2015 IPO schedule, a payment of $25,000 (the “Audit Controls Letter Retention Payment”) will be paid to you within thirty days following the
Audit Controls Letter Retention Date, which shall be defined as the earlier of (i) the completed crossover of $20 million or more from new investors or (ii) an IPO completion. 

 

	3.	Milestone 3 ($20 Million Plus Raise): If you satisfactorily support a crossover round resulting in a raise of at least $20 million from new investors, a payment of $25,000 (the “$20 Million Plus Raise
Retention Payment”) will be paid to you within thirty days following the completed crossover of $20 million or more from new investors (the “$20 Million Plus Raise Retention Date”). 

 

	4.	Milestone 4 (Initial S1 Filing): If you assist with Melinta’s successful filing of an initial S1 in the second quarter of 2015, a payment of $25,000 (the “Initial S1 Filing Retention Payment”) will
be paid to you within thirty days following the earlier of (i) the completed crossover of $20 million or more from new investors or (ii) an IPO completion (the “Initial S1 Filing Retention Date”). 

For avoidance of doubt, the total amount of the Retention Payment for which you may become eligible as of December 31, 2015 will be
reduced by any other retention payment you have already received (or become eligible to receive) (e.g., the Audit Retention Payment, the Audit Controls Letter Retention Payment, the $20 Million Plus Raise Retention Payment, and/or the Initial S1
Filing Retention Payment), such that, for example, if you have received all four of the referenced $25,000 retention payments, the payment for which you could become eligible on December 31, 2015, would be a total of up to $100,000. 

Finally, if Melinta terminates your employment prior to December 31, 2015 for any reason other than Cause (as defined below), you shall
be entitled to the entire Retention Payment within sixty days following the termination of your employment, less any other retention payments previously received by you, as described above. If this occurs, the entire Retention Payment will be paid
in addition to any severance for which you are eligible pursuant to the November 8, 2013 Severance Agreement. 
 Changes or Reductions in
Duties 
 By accepting this Agreement, you agree that during the remainder of your employment with Melinta, Melinta retains the right
to change your duties or responsibilities as an employee (including, but not limited to, reducing CFO-related duties and adding COO-related duties). It also includes our
right to maintain (or not maintain) your CFO title until the filing of an S1 (or until some other date). We trust that you will accommodate our need for flexibility during this time. For example, it may be necessary for you to undertake certain
additional or different duties and responsibilities appropriate for a COO here at Melinta. We are confident that you will accept any such additional or different duties and responsibilities with the same level of professionalism and capability that
you have demonstrated in the past. Any changes in duties or responsibilities referenced in this paragraph will in no way affect your entitlement to receive Retention Payment(s), or the amount of such payment(s). 

  
 2 

 Taxes 

Any payments made pursuant to this Agreement shall be subject to applicable tax or similar withholding requirements under applicable federal,
state or local employment or income tax laws or similar statutes or other provisions of law then in effect. It is the Company’s intention that all payments under this Agreement are exempt from or comply with the requirements of
Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and the regulations thereunder, including without limitation the six month delay for payments of deferred compensation to “key employees” upon
separation from service pursuant to Section 409A(a)(2)(B)(i) of the Code, if applicable, and this Agreement shall be interpreted, administered and operated accordingly. To the extent that any provision in this Agreement is ambiguous as to its
compliance with Section 409A, the provision shall be interpreted in a manner so that no payment due to you shall be deemed subject to an “additional tax” within the meaning of Section 409A(a)(1)(B) of the Code. Further, you shall
not be considered to have terminated employment with the Company for purposes of this Agreement unless you have incurred a “termination of employment” from the Company within the meaning of Treasury Regulation §1.409A-1(h)(1)(ii) promulgated under Section 409A of the Code. For purposes of Section 409A, each payment made under this Agreement shall be treated as a separate payment. In no event may you,
directly or indirectly, designate the calendar year of any payment under this Agreement. The Company does not guarantee the tax treatment of any payments under this Agreement, including without limitation under the Code, federal, state, local or
foreign tax laws and regulations. 
 Additional Information 

For purposes of this Agreement, “Cause” shall mean that you committed one or more acts or omissions constituting: (a) a felony;
(b) theft, misappropriation or embezzlement of Melinta funds; (c) fraud or self-dealing committed in conjunction with your employment; (d) a violation of laws, rules or regulations applicable to companies in the biotech industry
generally; (e) habitual intoxication or abuse of controlled substances; (f) unexplained absences from the office; (g) repeated and willful failure to follow supervisors’ reasonable instructions, or (h) your violation of any
Company policies or confidentiality responsibilities applicable to you. 
 Notwithstanding any of the foregoing, you remain an employee-at-will at all times and either you or Melinta may terminate the employment relationship at any time. 

This Agreement constitutes the entire agreement and understanding between Melinta and you relating to your eligibility to receive a Retention
Payment, and supersedes and cancels any and all prior and contemporaneous written and oral agreements and understandings, if any, between Melinta and you relating thereto. For avoidance of doubt, this Agreement does not supersede the Offer of
Employment dated March 16, 2015 or the November 8, 2013 Severance Agreement between Melinta and you. 
 This Agreement, the
underlying facts and circumstances, the Retention Payment are confidential. If you disclose or discuss this Agreement, these facts/circumstances, or these payments or benefits with anyone other than direct family members, or legal or tax advisors,
the Retention Payment may be forfeited. 

  
 3 

 Please feel free to contact me with any questions regarding this Agreement. 

 

					
		 		 	Very truly yours,
			
		 		 	 /s/ Mary Szela

		 		 	Mary Szela 
		 		 	CEO
	Accepted and agreed:	 		 	Melinta Therapeutics, Inc.
			
	/s/ Paul D. Estrem	 		 	3/16/15
	  
 Paul Estrem
	 		 	  
 Date

  
 4EX-10.3

 Exhibit 10.3 

Execution Version 
  
 

 
 August 29, 2017 

Paul Estrem 
 13 N Lake Ave. 

Third Lake, IL 60030 
 RE: Amended and
Restated Severance Agreement 
 Dear Paul: 

You are a key member of the senior management team of Melinta Therapeutics, Inc. (the “Company”). As a result, the Company is
providing you with the following benefits in consideration of your continued employment with the Company. 
  

	I.	Definitions. For the purposes of this Amended and Restated Severance Agreement (this “Agreement”), which is intended to amend and restate your prior Severance Agreement, dated August 23,
2015 (the “Prior Agreement”), capitalized terms shall have the following meanings: 

  

	 	1.	“Cause” shall mean: 

  

	 	(a)	your conviction of or your plea of guilty to or confession of an act of fraud, misappropriation or embezzlement or any felony; 

  

	 	(b)	your willful refusal or failure to follow a lawful directive or instruction of the Company’s board of directors or the individual(s) to whom you report; 

 

	 	(c)	in carrying out your duties, you commit material dishonesty or you breach a fiduciary duty to the Company; 

  

	 	(d)	you engage in conduct which causes material injury to the Company, monetarily or otherwise; 

  

	 	(e)	you use illegal substances at any time; or 

  

	 	(f)	you materially breach any Company policies regarding confidentiality, insider trading, any employment agreement with the Company then in effect or your Employee Noncompetition, Nondisclosure and Developments Agreement.

  

	 	2.	“Change in Control” shall mean the date: 

  

	 	(a)	any “person” or “group” (as such terms are used in Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) is or becomes the beneficial owner of our securities representing
50% or more of the total voting power of the Company’s then-outstanding voting securities, pursuant to a transaction which the Company’s board of directors does not approve; 

	 	(b)	the Company undergoes a merger, reorganization or other consolidation, including the sale of substantially all of the Company’s assets, in which the Company is not the surviving entity and in which the persons
holding the Company’s outstanding equity immediately prior to such merger, reorganization or consolidation own less than 50% of the surviving entity’s voting power immediately after the transaction; or 

 

	 	(c)	a change in the composition of the Company’s board of directors, as a result of which fewer than a majority of the directors are incumbent directors. Incumbent directors shall mean directors who either
(A) were Company directors as of the date of this Agreement, or (B) are elected, or nominated for election, to the Company’s board of directors with the affirmative votes of at least a majority of the incumbent directors at the time
of such election or nomination, but shall not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of members to the Company’s board of directors.

 And provided further that in each of the foregoing cases, the Change in Control also meets all of the requirements of a
“change in the ownership of a corporation” within the meaning of Treasury Regulation § 1.409A-3(i)(5)(v), a “change in the effective control of a corporation” within the meaning of Treasury Regulation §
1.409A-3(i)(5)(vi) or a “a change in the ownership of a substantial portion of the corporation’s assets” within the meaning of Treasury Regulation § 1.409A-3(i)(5)(vii). 

 

	 	3.	“Code” shall mean the Internal Revenue Code of 1986, as amended. 

  

	 	4.	“Disability” shall mean a disability as determined under the Company’s long-term disability plan or program in effect at the time the disability first occurs, or if no such plan or program exists
at the time of disability, then a “disability” as defined Section 22(e)(3) of the Code. 

  

	 	5.	“Good Reason” shall mean one of the following events has occurred without your consent: 

  

	 	(a)	your annual base salary is decreased; 

  

	 	(b)	your principal place of employment is relocated to a place 35 or more miles away from one of the Company’s locations; or 

  

	 	(c)	the Company breaches the material terms of any employment agreement then in effect or you experience a material adverse change to your primary responsibilities or duties. 

And provided further that Good Reason shall not exist unless and until within 90 days after the event giving rise to Good Reason under (a),
(b) or (c) above has occurred, you deliver a written termination notice to the Company stating that an event giving rise to Good Reason has occurred and identifying with reasonable detail the event that you assert constitutes Good Reason under
(a), (b) or (c) above and the Company fails or refuses to cure or eliminate the event giving rise to Good Reason on or within 30 days after receiving your notice. To avoid doubt, the termination of your employment would become effective at the
close of business on the thirtieth day after the Company receives your termination notice, unless the Company cures or eliminates the event giving rise to Good Reason prior to such time. 

 

	 	6.	“Termination Date” shall mean the last day of your employment with the Company. 

  

	II.	Severance Benefits 

  

	 	1.	Severance shall be paid to you if your employment is terminated by the Company (except for termination for Cause or due to death or a Disability) or if you, of your own initiative, terminate your employment for Good
Reason (in accordance with the notice and cure provisions in this Agreement), provided that the termination of your employment also constitutes a “separation from service” as defined by Code Treasury Regulation § 1.409A-1(h). 

  
 Page 2 

	 	2.	In the event you are eligible for severance, the Company shall make a cash payment (the “Severance Payment”) to you in an amount equal to twelve months of your annual base salary (less applicable
withholdings) on a payroll basis (provided, however, that if you terminate your employment for Good Reason based on a reduction in your annual base salary, then the annual base salary to be used in calculating the Severance Payment shall be your
annual base salary in effect immediately prior to such reduction in annual base salary). If you are covered under the Company’s group medical and dental coverage as of the Termination Date, and if you are eligible to continue such coverage
pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company will reimburse the employer portion of the premium costs (consistent with the Company’s policy for active employees) of
such continuation coverage until the earlier of (i) the end of the twelfth month following the Termination Date; or (ii) the date that you become eligible for coverage under another group health plan. 

 

	 	3.	The Severance Payment will only be made in exchange for a general release to be executed by you, which becomes enforceable and irrevocable within 60 days of your Termination Date, of all claims against the Company, its
subsidiaries, and its and their officers, directors and representatives, in a form satisfactory to the Company. The Severance Payment shall begin within ten days after the execution by you of the general release and expiration without revocation of
any applicable revocation periods under such general release, provided that, if the 60 day period during which the release is required to become effective and irrevocable begins in one calendar year and ends in another calendar year, the Severance
Payment shall be made in the second calendar year. 

  

	 	4.	You shall not be required to mitigate the amount of the Severance Payment or any other benefit provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit
provided for in this Agreement be reduced (except as provided in this Agreement) by any compensation earned by you as the result of other employment, by retirement benefits, or be offset against any amount claimed to be owed by you to the Company or
otherwise (except for any required withholding taxes); provided, that if the Company makes any other severance payments to you under any other program or agreement, such amounts shall be offset against the payments the Company is obligated to make
pursuant to this Agreement. 

  

	III.	Pro-Rated Bonus upon Change in Control 

 If,
within six (6) months of the effective date of a Change in Control, you are terminated without Cause or you resign for Good Reason, you will be entitled to the pro-rata portion of the annual bonus for the
year in which the termination of your employment occurs, based on the number of months of completed employment up to the Termination Date, payable no later than March 1 of the following year, in one
lump-sum amount (less required withholdings). 
  

	IV.	Miscellaneous. 

  

	 	1.	Section 409A Compliance. The payments and benefits provided for in Section II of this Agreement constitute an involuntary separation plan pursuant to Treas. Reg. § 1.409A-1(n), and thus is not “non-qualified deferred compensation” subject to Section 409A of the Code. To the extent that any of the payments or benefits
provided for in Section II are deemed to constitute non-qualified deferred compensation benefits subject to Section 409A of the Code, however, the following interpretations apply: Any termination of your
employment triggering payment of benefits under Section II must constitute a “separation from service” under Section 409A(a)(2) (A)(i) of the Code and Treasury Regulation § 1.409A-1(h)
before distribution of such benefits can commence. To the extent that the termination of your employment does not constitute a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treasury Regulation § 1.409A-1 (h) (as the result of further services that are reasonably anticipated to be provided by you to the Company or any of its parents, subsidiaries or affiliates at the time your employment terminates), any
benefits payable under Section II that constitute deferred compensation under Section 409A of the Code shall be delayed until after the date of a subsequent event constituting a separation of service under Section 409A(a)(2)(A)(i) of the
Code and Treasury Regulation § 1.409A-1(h). For purposes of 

  
 Page 3 

	 	
clarification, this Section shall not cause any forfeiture of benefits on your part, but shall only act as a delay until such time as a “separation from service” occurs. Further, if you
are a “specified employee” (as that term is used in Section 409A of the Code and regulations and other guidance issued thereunder) on the date a separation from service becomes effective, any benefits payable under Section II that
constitute non-qualified deferred compensation under Section 409A of the Code shall be delayed until the earlier of (i) the business day following the
six-month anniversary of the date your separation from service becomes effective, and (ii) the date of your death, but only to the extent necessary to avoid such penalties under Section 409A of the
Code. On the earlier of (i) the business day following the six-month anniversary of the date your separation from service becomes effective, and (ii) your death, the Company shall pay you (or your
estate) in a lump sum the aggregate value of the non-qualified deferred compensation that the Company otherwise would have paid you prior to that date under Section II of this Agreement. It is intended that
each installment of the payments and benefits provided under Section II of this Agreement shall be treated as a separate “payment” for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to
accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code. 

  

	 	2.	Employee’s Obligations. Upon the termination of employment, you shall promptly deliver to the Company all property of the Company and all material documents, data and other items which may be in your
possession or under your control and which relate in a material way to the business or affairs of the Company or its subsidiaries, and no copies of any such documents or any part thereof shall be retained by you. Any post-employment obligations you
may have pursuant to separate agreements supplement but do not supersede this Agreement and shall survive as provided for in such separate agreements. 

  

	 	3.	Entire Agreement. This Agreement and any employment letter or confidentiality and non-competition and equity agreements previously executed by you covers the entire understanding of the parties as to the subject
matter hereof, superseding all prior understandings and agreements related hereto, including, but not limited to, the Prior Agreement. No modification or amendment of the terms and conditions of this Agreement shall be effective unless in writing
and signed by the parties or their respective duly authorized agents. 

  

	 	4.	Governing Law. This Agreement shall be governed by the laws of the State of New York, without giving effect to any principles of conflicts of laws. 

 

	 	5.	Successors and Assigns. This Agreement may be assigned by the Company upon a sale, transfer or reorganization of the Company. Upon a Change in Control, the Company shall require the successor to assume the
Company’s rights and obligations under this Agreement. The Company’s failure to do so shall constitute a material breach of this Agreement. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their
successors, permitted assigns, legal representatives and heirs. 

  
 Page 4 

 Kindly indicate your acceptance of the foregoing by signing and dating this Agreement as noted
below, and returning one fully executed original to my attention. 
  

			
	 Very truly yours,
  

Melinta Therapeutics, Inc.
  

Dr. Eugene Sun
 Chief Executive
Officer

		
	By:	 	 /s/ Dr. Eugene Sun

 ACCEPTED AND AGREED: 
  

	
	Paul Estrem
	
	/s/ Paul Estrem
	[NAME]
	
	9-1-17
	DATE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]